Livcare (Obeticholic Acid) is a selective Farnesoid X Receptor (FXR) agonist with anticholestatic & hepato-protective properties. Due to these promising effects, Livcare (Obeticholic Acid) is a novel treatment option for Non-Alcoholic Fatty Liver Disease (NAFLD) including Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC). Its multiple mechanism, metabolic effects & convenient once daily dose ensure clear superiority over Ursodeoxycholic Acid (UDCA). Obeticholic acid (Livcare) is also recommended and approved by USFDA, European Medicine Agency and American College of Gastroenterology society.
FR
DE